Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

Nature Biotechnology

Volumn 31, Issue 6, 2013, Pages 539-544

  Baccelli, Irène ^a,b   Schneeweiss, Andreas ^c   Riethdorf, Sabine ^d   Stenzinger, Albrecht ^c   Schillert, Anja ^a,b   Vogel, Vanessa ^a,b,c   Klein, Corinna ^a,b   Saini, Massimo ^a   Bäuerle, Tobias ^b   Wallwiener, Markus ^c   Holland Letz, Tim ^b   Höfner, Thomas ^a,b   Sprick, Martin ^a,b   Scharpff, Martina ^c   Marmé, Frederik ^c   Sinn, Hans Peter ^c   Pantel, Klaus ^d   Weichert, Wilko ^c   Trumpp, Andreas ^a,b  

^a Exp Hematology Group Heidelberg Institute for Stem Cell Technology and Experimental Medicine GGmbH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CIRCULATING TUMOR CELLS; LIVER METASTASIS; OVERALL SURVIVAL;

BLOOD; CELLS; DIAGNOSIS; DISEASES;

PATHOLOGY;

CD47 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CIRCULATING TUMOR CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; BREAST NEOPLASMS; CELL COUNT; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880270290     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2576     Document Type: Article

References (43)

1. Kim, M.Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326 (2009).
2. Nguyen, D.X., Bos, P.D. & Massague, J. Metastasis: from dissemination to organspecific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
3. Pantel, K., Alix-Panabieres, C. & Riethdorf, S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 6, 339-351 (2009).
4. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
5. Yu, M., Stott, S., Toner, M., Maheswaran, S. & Haber, D.A. Circulating tumor cells: approaches to isolation and characterization. J. Cell Biol. 192, 373-382 (2011).
6. Krebs, M.G. et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 29, 1556-1563 (2011).
7. Cohen, S.J. et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 20, 1223-1229 (2009).
8. de Bono, J.S. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302-6309 (2008).
9. Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791 (2004).
10. Budd, G.T. et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12, 6403-6409 (2006).
11. Kling, J. Beyond counting tumor cells. Nat. Biotechnol. 30, 578-580 (2012).
12. Kalluri, R. & Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009).
13. Rhim, A.D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
14. Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584 (2013).
15. Braun, S. et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353, 793-802 (2005).
16. Shiozawa, Y. et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298-1312 (2011).
17. Riethdorf, S. et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13, 920-928 (2007).
18. Ito, M. et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175-3182 (2002).
19. Mazurier, F., Doedens, M., Gan, O.I. & Dick, J.E. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat. Med. 9, 959-963 (2003).
20. Lapidot T., Dar A. & Kollet, O. How do stem cells find their way home? Blood 106, 1901-1910 (2005).
21. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. & Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983- 3988 (2003).
22. Liu, H. et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl. Acad. Sci. USA 107, 18115-18120 (2010).
23. Willingham, S.B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA 109, 6662-6667 (2012).
24. Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
25. Chao, M.P. et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71, 1374-1384 (2011).
26. Chan, K.S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. USA 106, 14016-14021 (2009).
27. Chao, M.P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699-713 (2010).
28. Edris, B. et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl. Acad. Sci. USA 109, 6656-6661 (2012).
29. Nagahara, M. et al. Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin. Cancer Res. 16, 4625-4635 (2010).
30. Trusolino, L., Bertotti, A. & Comoglio, P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834-848 (2010).
31. Orian-Rousseau, V. CD44, a therapeutic target for metastasising tumours. Eur. J. Cancer 46, 1271-1277 (2010).
32. Shibue, T. & Weinberg, R.A. Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin. Cancer Biol. 21, 99-106 (2011).
33. Kasimir-Bauer, S., Hoffmann, O., Wallwiener, D., Kimmig, R. & Fehm, T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 14, R15 (2012).
34. Powell, A.A. et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 7, e33788 (2012).
35. Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235-1239 (2007).
36. Stott, S.L. et al. Isolation of circulating tumor cells using a microvortex-generating herringbone- chip. Proc. Natl. Acad. Sci. USA 107, 18392-18397 (2010).
37. Chao, M.P., Majeti, R. & Weissman, I.L. Programmed cell removal: a new obstacle in the road to developing cancer. Nat. Rev. Cancer 12, 58-67 (2012).
38. Orian-Rousseau, V., Chen, L., Sleeman, J.P., Herrlich, P. & Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16, 3074-3086 (2002).
39. Baccelli, I. & Trumpp, A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 198, 281-293 (2012).
40. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
41. Chao, M.P., Weissman, I.L. & Majeti, R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225-232 (2012).
42. Gherardi, E., Birchmeier, W., Birchmeier, C. & Woude, G.V. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12, 89-103 (2012).
43. Riethdorf, S. et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 16, 2634-2645 (2010).